Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Two years after premiering a 13-minute documentary about three eczema patients, Abbvie has again teamed with branded entertainment firm Passion Point Collective, this time for a 16-minute documentary ...

Terry Evans is in a paid partnership with Lilly and has been compensated for his time. Like many parents back in the 1990s, Terry Evans of Huntington Beach, Calif., was wrapped up in his job and ...

RedHill Biopharma ( (RDHL)) has provided an update. On December 15, 2025, RedHill Biopharma announced positive in vivo results for opaganib, showing its potential to reduce Chronic Lymphocytic ...

Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie, in collaboration with Hoffmann-La Roche and the German CLL Study Group, has completed a Phase III clinical trial titled ‘A ...

Forskolin, a plant-derived compound, shows surprising potential against one of the most aggressive forms of leukemia. Researchers discovered that it not only stops cancer cells from growing but also ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

Joanna Rhodes, MD, MSCE, highlights significant racial and ethnic disparities that persist in access to preferred CLL treatments. What do your findings reveal about the magnitude of racial and ethnic ...

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) ...